Orphan Drug Designations as Valuable intangible assets for Ipo Investors in Pharma-biotech companies

Diego Useche and Philippe Gorry

Post-Print from HAL

Date: 2015-06-27
References: Add references at CitEc
Citations:

Published in 65th Annual Meeting of the French Economic Association,, Jun 2015, Nancy, France

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
Chapter: Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies (2018)
Working Paper: Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies (2017)
Working Paper: Orphan Drug Designations as valuable Intangible assets for IPO Investors in Pharma-Biotech Companies (2016)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-02195963

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().